<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364550">
  <stage>Registered</stage>
  <submitdate>5/07/2013</submitdate>
  <approvaldate>9/07/2013</approvaldate>
  <actrnumber>ACTRN12613000767707</actrnumber>
  <trial_identification>
    <studytitle>Meloxicam effects on vasospasm in subarachnoid hemorrhage</studytitle>
    <scientifictitle>Comparative efficacy of Meloxicam and placebo on vasospasm in patients with subarachnoid hemorrhage (SAH) in Shariati Hospital</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>subarachnoid hemorrhage</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>In this randomized, double-blind, placebo-controlled trial, SAH patients randomly received 7.5 mg oral tablet meloxicam or placebo twice daily for 7 days. Since patients were hospitalized all of the medication administered by nurses. 
</interventions>
    <comparator>Control group received placebo of meloxicam twice daily for 7 days. Placebo tablets were provided by the meloxicam company, tablets included all ingredients except meloxicam.  </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Middle cerebral artery (MCA) velocity obtained with transcranial doppler
</outcome>
      <timepoint>Base line, 4 days after taking drug, last day of taking drug</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Glasgow Outcome Scale </outcome>
      <timepoint>discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Length of hospital stay</outcome>
      <timepoint>at discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with diagnosis of subarachnoid hemorrhage documented by Computed Tomography (CT) scan  who admitted to neurosurgery and neurology wards of Shariati hospital.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Meloxicam contraindications: Meloxicam, aspirin, or any other NSAIDs sensitivity
Serious adverse reaction induced by meloxicam
Long term use of meloxicam or any other NSAIDs before the study
Occurrence of rebleeding in patient leading to emergency neurosurgical operation
Serious interaction between patient's medications and meloxicam
Unstable hemodynamic condition in patient making doppler sonography impossible
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate>7/04/2011</actualstartdate>
    <anticipatedenddate>7/10/2012</anticipatedenddate>
    <actualenddate>21/02/2013</actualenddate>
    <samplesize>106</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Enghlab Street, Poursina Street, Tehran, Iran
Postal code:14161351</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tehran University of Medical Sciences</fundingname>
      <fundingaddress>Enghlab Street, Poursina Street, Tehran, Iran
Postal code:14161351</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cerebral vasospasm influences morbidity and mortality following subarachnoid haemorrhage (SAH). Current therapeutic protocols do not show enough therapeutic effects in prevention and treatment of vasospasm. Inflammation is believed to play an important role in post-haemorrhagic vasospasm. Meloxicam is a non-steroidal anti-inflammatory drug.
The aim of the study is investigation the comparative efficacy of meloxicam and plasebo on vasospasm in patients with SAH in Shariati Hospital.
In this randomized, double-blind, placebo-controlled trial, SAH patients randomly received 7.5 mg meloxicam or placebo twice daiy for 7 days. End points were, middle cerebral artery (MCA) velocity obtained with transcranial doppler, length of hospital stay and discharge Glasgow Outcome Scale scores.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Soheil Naderi</name>
      <address>12, Habib Chizari Alley. ,Andarzgoo Blvd. ,Kamranieh St. ,Tehran, Iran. Postal code:1917845654
Neurosurgery Department, Tehran University of Medical Sciences.</address>
      <phone>+989123279808</phone>
      <fax />
      <email>soheilnaaderi@Gmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Niayesh Mohebbi</name>
      <address>62, Proshat,Shekarabi,Shariati
Tehran, Iran. Postcode: 1567716195
Clinical Pharmacy Department, Tehran University of Medical Sciences.</address>
      <phone>+989121781476</phone>
      <fax />
      <email>nmohebbi@razi.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Niayesh Mohebbi</name>
      <address>62, Proshat,Shekarabi,Shariati
Tehran, Iran. Postcode: 1567716195
Clinical Pharmacy Department, Tehran University of Medical Sciences.</address>
      <phone>+989121781476</phone>
      <fax />
      <email>nmohebbi@razi.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>